Dana Bright, NP
Adult Health · Spartanburg, SCNPI 1497166318
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations.
Across 275 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$692
- Novo Nordisk$414
- Novartis$367
- Pfizer$307
- Astellas Pharma US Inc$237
- Amgen$180
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,51998%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $692 |
| Novo Nordisk | 29 | $414 |
| Novartis | 19 | $367 |
| Pfizer | 19 | $307 |
| Astellas Pharma US Inc | 9 | $237 |
| Amgen | 12 | $180 |
| Sumitomo Pharma America, Inc. | 9 | $178 |
| Dexcom, Inc. | 11 | $170 |
| Bayer | 10 | $167 |
| Lilly USA, LLC | 11 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $145 |
| Abbott | 6 | $125 |
| Eisai Inc. | 6 | $117 |
| Daiichi Sankyo Inc. | 5 | $117 |
| AstraZeneca | 7 | $112 |
| Exact Sciences | 6 | $99 |
| Boehringer Ingelheim | 5 | $93 |
| GSK | 6 | $92 |
| Supernus Pharmaceuticals, Inc. | 5 | $91 |
| Amarin Pharma, Inc. | 6 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Sanofi-aventis U.S. LLC | 4 | $67 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Inari Medical, Inc. | 2 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Corcept Therapeutics | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Johnson & Johnson | 1 | $21 |
| Tonix Medicines, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Ardelyx, Inc. | 1 | $16 |
| Corium, LLC | 1 | $16 |
| IBSA Pharma Inc. | 1 | $12 |
| Organon | 1 | $10 |
How this compares
$4,613 in reported general payments places this provider in the 80th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $18,827 |
| PaxlovidNirmatrelvir/Ritonavir | 25 | $1,429 |
| Doxycycline Hyclate | 196 | $1,347 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,228 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 146 | $1,093 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 125 | $824 |
| SynthroidLevothyroxine Sodium | 14 | $771 |
| Azithromycin | 188 | $683 |
| Metronidazole | 44 | $626 |
| Cefdinir | 27 | $580 |
| Prednisone | 301 | $491 |
| Potassium Chloride | 24 | $464 |
| Duloxetine Hcl | 11 | $408 |
| Fluconazole | 79 | $402 |
| Pantoprazole Sodium | 33 | $356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $307 | $20,25642 claims |
| AbbVieSynthroid | $692 | $77114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 292 adult health providers in South Carolina.
Other adult health in Spartanburg
- Melissa McCarterSpartanburg$12K
- Nichole SnowSpartanburg$10K
- Crystal HumphriesSpartanburg$7K
- Amy ClintonSpartanburg$7K
- Marva ThomasSpartanburg$5K
- Shareda YoungSpartanburg$4K
- Karen RobertsonGreenville$69K
- Christine FranzeseTega Cay$30K
- Jessica RiceGreenville$15K
- Michelle PriceCharleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.